NASDAQ:ANIP ANI Pharmaceuticals Q2 2025 Earnings Report $72.58 +0.40 (+0.55%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$71.66 -0.92 (-1.27%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ANI Pharmaceuticals EPS ResultsActual EPS$1.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AANI Pharmaceuticals Revenue ResultsActual Revenue$211.37 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AANI Pharmaceuticals Announcement DetailsQuarterQ2 2025Date9/8/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsANI Pharmaceuticals' Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile ANI Pharmaceuticals Earnings HeadlinesComparing Sunshine Biopharma (NASDAQ:SBFM) and ANI Pharmaceuticals (NASDAQ:ANIP)October 5 at 4:30 AM | americanbankingnews.comANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual MeetingSeptember 30, 2026 | globenewswire.comThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and America's $40 trillion national debt to a potential surge in gold prices, with some forecasts pointing to $10,000 or even $20,000 gold. Dr. David Eifrig, a 40-year market veteran and former Goldman Sachs Vice President, says an unusual plan involving Trump and two other top officials could fuel the biggest gold bull run in decades. Eifrig has shared his top gold pick tied to this developing story. | Stansberry Research (Ad)ANI Pharmaceuticals (NASDAQ:ANIP) & Heron Therapeutics (NASDAQ:HRTX) Head to Head ReviewSeptember 26, 2026 | americanbankingnews.comANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The BuildSeptember 24, 2026 | seekingalpha.comOcular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To KnowSeptember 23, 2026 | finance.yahoo.comSee More ANI Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ANI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ANI Pharmaceuticals and other key companies, straight to your email. Email Address About ANI PharmaceuticalsANI Pharmaceuticals (NASDAQ:ANIP) is a specialty pharmaceutical company that develops, manufactures and commercializes branded and generic prescription medicines. The company focuses on products with complex formulations, difficult-to-manufacture dosage forms and limited competition, serving therapeutic areas that include rare diseases, ophthalmology, endocrinology, central nervous system conditions and other specialty markets. ANI’s portfolio includes Cortrophin Gel (repository corticotropin injection), a specialty therapy used for certain inflammatory and autoimmune conditions, as well as a range of established brand and generic products. Through its acquisition of Alimera Sciences, ANI expanded its ophthalmology business with products such as ILUVIEN and YUTIQ, which are used in the treatment of retinal diseases. The company also operates pharmaceutical manufacturing and development capabilities in the United States. ANI primarily serves the U.S. prescription pharmaceutical market through commercial, specialty and institutional channels. The company’s history includes the expansion of its product portfolio through acquisitions and the development of higher-value specialty medicines alongside its established generic and branded products. Nikhil Lalwani serves as ANI Pharmaceuticals’ president and chief executive officer.View ANI Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
